

Evaluation of and expected access to new RSV vaccines and long-acting monoclonal antibody (mAB) in Australia as at 12 January 2026

Formal recommendations regarding the use of RSV immunisation products in Australia can be found in the [Australian Immunisation Handbook RSV chapter](#).

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee (PBAC) assessment for funding	National Immunisation Program (NIP) inclusion/funded supply	Private market supply	Clinical guidance
Infant protection						
Nirsevimab (Beyfortus, Sanofi-Aventis; long-acting monoclonal antibody)	Newborns/infants and children aged up to 24 months with risk conditions	TGA approved in November 2023	May 2025	No ; PBAC decision has been deferred State- and territory-funded programs	No	Recommended in certain infants and children
Abrysvo (Pfizer; protein subunit vaccine)	Infants from birth through 6 months of age, by active immunisation of pregnant individuals	TGA approved in March 2024	March 2024 and May 2024	Yes ; program commenced 3 February 2025	Available	Recommended in pregnant women from 28 weeks gestation

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee (PBAC) assessment for funding	National Immunisation Program inclusion/funded supply	Private market supply	Clinical guidance
Older adults protection						
Abrysvo (Pfizer; protein subunit vaccine)	Adults aged ≥60 years	TGA approved in March 2024	November 2024	<p>A funded program has not commenced, but PBAC has given a positive recommendation for:</p> <ul style="list-style-type: none"> all adults aged ≥75 years Aboriginal and Torres Strait Islander adults aged 60–74 years <p>Funding for adults with risk conditions aged ≥60 years to be addressed in a future resubmission</p>	Available	<p>Recommended in:</p> <ul style="list-style-type: none"> all adults aged ≥75 years adults with risk conditions <i>and</i> Aboriginal and Torres Strait Islander adults aged ≥60 years

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee (PBAC) assessment for funding	National Immunisation Program inclusion/funded supply	Private market supply	Clinical guidance
Older adults protection						
Arexvy (GSK; protein subunit vaccine with adjuvant)	Adults aged ≥60 years	TGA approved in January 2024	July 2025	<p>A funded program has not commenced, but PBAC has given a positive recommendation for:</p> <ul style="list-style-type: none"> all adults aged ≥75 years First Nations adults aged 60–74 years <p>Funding for adults with risk conditions aged ≥60 years to be addressed in a future resubmission</p> <p>State and territory funded programs: Funded in Victoria for residents aged ≥60 years in public and Aboriginal community-controlled aged care services</p>	Available	<p>Recommended in:</p> <ul style="list-style-type: none"> all adults aged ≥75 years adults with risk conditions <i>and</i> Aboriginal and Torres Strait Islander adults aged ≥60 years

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee (PBAC) assessment for funding	National Immunisation Program inclusion/funded supply	Private market supply	Clinical guidance
	Adults aged 50–59 years with risk conditions	TGA approved in March 2025	TBD	TBD	Available	Consider in: <ul style="list-style-type: none"> adults with risk conditions aged 50–59 years
mRESVIA (Moderna; mRNA vaccine)	Adults aged ≥60 years	TGA approved in March 2025	November 2025	No ; PBAC decision has been deferred	Currently not available	n/a